Multiomics reveals gut dysbiosis contributes to fatty acid dysmetabolism in early phase of acute myocardial infarction

3

4 Authors

Yong Fan^a, Jiajun Ying^{a,b,c}, Ning Huangfu^{a,b,c}, Kewan He^{a,d}, Teng Hu^a, Pengpeng Su^e,
 Xintao Hu^a, Hequn He^f, Wei Liang^g, Junsong Liu^b, Jinsong Cheng^b, Shiqi Wang^b, Ruochi
 Zhao^b, Hengyi Mao^b, Fuwei He^b, Jia Su^b, Honglin Zhou^b, Zhenwei Li^b, Xiaohong Fei^b,

8 Xiafei Sun^b, Peipei Wang^b, Minfang Guan^b, Weiping Du^b, Shaoyi Lin^b, Yong Wang^b,

9 Fangkun Yang^a, Renyuan Fang^b, Ziqing Kong^h, Xiaomin Chen^{a,b,c*}, Hanbin Cui^{a,b,c*}

10 Yong Fan and Jiajun Ying contributed equally to this work.

11

12 Affiliations

^a Key Laboratory of Precision Medicine for Atherosclerotic Diseases of Zhejiang
 Province, The First Affiliated Hospital of Ningbo University, Ningbo 315000, China.

^b Cardiology Center, The First Affiliated Hospital of Ningbo University, Ningbo 315000,

16 China.

^c Ningbo Clinical Research Center for Cardiovascular Disease, Ningbo 315000, China.

^d Present address: Department of Ultrasound, The Affiliated Hospital of Ningbo

19 University, LiHuiLi Hospital, Ningbo 315040, China.

^e Wenzhou Medical University, Wenzhou 325035, China.

^f Department of Emergency, The First Affiliated Hospital of Ningbo University, Ningbo
 315000, China.

^g Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo
 315000, China.

²⁵ ^h Calibra Lab in DI'AN Diagnostics, Key Laboratory of Digital Technology in Medical

26 Diagnostics of Zhejiang Province, Hangzhou 310030, China.

27

28 * Corresponding author: X.C. (email: <u>chxmin@hotmail.com</u>) or

29 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 Abstract

Background: Acute myocardial infarction (AMI) remains a major cause of death, with limited understanding of its early risk stratification. While late-stage AMI has recognized associations with gut microbiome disturbances, the connection to eAMI is less explored.

Methods: Using metabolomics and metagenomics, we analyzed 56 samples, comprising 30 eAMI patients (within 12 hours of onset) and 26 age- and gendermatched healthy controls, to discern the influence of gut microbes and their metabolites.

Results: We found the eAMI plasma is dominated by increased long-chain fatty acids 39 (LCFAs), 14 of which provide differentiating power of eAMI patients from HCs. 40 Multiomics analysis reveals up to 70% of the variance in LCFAs of eAMI patients can 41 be explained by altered gut microbiome. Higher-resolution profiling of gut bacterial 42 species demonstrated that bacterial structural variations are mechanistically linked to 43 44 LCFAs dysregulation. By *in silico* molecular docking and *in vitro* thrombogenic assay in isolated human platelets, we highlighted that eAMI-associated LCFAs contribute to 45 platelet aggregation, a driving factor for AMI initiation. 46

47 **Conclusions:** LCFAs hold significant potential as early biomarkers of AMI and gut 48 microbiome contributes to altered LCFAs in eAMI. Further studies are imperative to 49 expand upon these observations to better leverage LCFAs as a potential biomarker 50 for eAMI and as a therapeutic target for inhibition of platelet aggregation in eAMI.

- 51
- 52

53 Introduction

Acute myocardial infarction (AMI), the most lethal type in coronary artery disease 54 (CAD) and primary cause leading to human mortality and morbidity(1-3), is mainly 55 resulted from the rupture or erosion of atherosclerotic plague, accompanied by the 56 formation of an occlusive or sub-occlusive thrombus in one or more coronary artery 57 branches(4,5). Accordingly, AMI is divided into two subtypes, ST-segment elevation 58 myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction 59 (NSTEMI). It has been showed that systemic or local inflammation, imbalance in 60 adaptive immune pathways can modulate atherosclerotic plaque activity and 61 contribute to coronary dysfunction and myocardial ischemic necrosis(5-7). However, 62 63 the exact underlying mechanism responsible for the progression of coronary artery 64 disease and occurrence of adverse event remains unclear.

65 A rising body of epidemiological study suggests that gut microbiota have a pivotal 66 role in low-grade inflammatory metabolic diseases such as obesity(8) and diabetes(9), which are considered risk factor for atherosclerotic development. 67 Thereafter, pathological evidence indicates that bacteria from the gut or the oral 68 cavity might translocate to and reside in atherosclerotic plaques and could affect the 69 70 development of atherosclerotic cardiovascular disease (ASCVD)(10,11). Improved sequencing technology and bioinformatics analyses have provided the several 71 72 significant associations between the microbiota taxa and ASCVD(12,13).

On how gut microbiota promote to the development of ASCVD, we have summarized 73 74 recent advances in the atherosclerosis-linked alterations in gut microbiome, highlighting the microbiota-related circulating metabolites that accelerate the 75 ASCVD(14). Microbiota-synthesized 76 development of metabolites such as secondary bile 77 trimethylamine N-oxide, acids, short-chain fatty acids, lipopolysaccharides and phenylacetylglutamine have been recognized as the 78 important contributor to atherosclerotic consequences. Nevertheless, whether gut 79 microbiota participate in the initiation of AMI, some observational study reported 80 the statistical correlation between gut bacteria profiling and AMI clinical phenotype. 81 82 However, results are inconsistent across previous findings(15,16).

So far, the reported investigations on the associations between intestinal microbes 83 and AMI recruited mostly patients in the late or stable stage of AMI, sparse report on 84 very early phase of disease has been shown. Whether gut microbes contribute to the 85 86 early stage of AMI (eAMI) lesion through its derived metabolites remains unknown. Here, we recruited a cohort of 30 patients with eAMI within 12 hours and 26 normal 87 controls, for whom we performed metagenomic sequencing of the gut microbiome 88 and plasma metabolomics. We found that long-chain fatty acids (LCFAs) dominate 89 the metabolome perturbations in eAMI plasma, and the gut microbiome at species 90 level explains up to 70% of the variance in LCFAs composition in eAMI patients. We 91 92 also found that eAMI-associated LCFAs may possess potent thrombogenic 93 functionality by molecular docking and platelet aggregation assay, which furtherly 94 supports the rational for causal relationship between altered gut microbiota and the initiation of AMI. 95

96

98 Materials and methods

99 Study design and cohort description

This study enrolled 30 AMI patients and 26 normal controls who were hospitalized in the First Affiliated Hospital of Ningbo University from February 2021 to November 2021. Participants were in strictly conformity with the inclusion and exclusion criteria (**Figure S1**). The diagnosis of AMI is based on the guidelines of the American Heart Association (ACC) in 2021(17).

Inclusion criteria were diagnoses of AMI defined as follows: cardiac troponin (cTn)
I/T > the upper limit of the 99% normal reference value and have any one or more of
the following: significant chest pain of myocardial ischemia; changes in newly
diagnosed ischemic electrocardiogram (ST-T changes or left bundle branch block or
pathological Q wave); imaging evidence suggested new loss of myocardial activity or
regional wall motion abnormalities; abnormal coronary angiography.

Exclusion criteria were: history of digestive diseases; severe hepatic and renal dysfunction; history of autoimmune diseases, malignant hematological diseases and tumor; infection within one month of the study or the use of antibiotic or probiotic. Normal controls were hospitalized for health examination at the same period.

The study protocol was approved by the Ethics Committee of The First Affiliated Hospital of Ningbo University (No. 2021-R018-YJ01). The study was performed in accordance with the principles of the Declaration of Helsinki. All participants provided written, informed consent for participation in the study.

119 Sample collection and biochemical analysis

Peripheral venous blood was drawn immediately after the patients arrived at the emergency department, or first moments after hospitalization for normal control individuals. Blood samples were centrifuged immediately at 4 °C, 4000 rpm for 10 minutes, and the supernatant (plasma) was stored at -80 °C for further analysis. The first morning fresh fecal (each 400-600 mg) and urine samples were collected from all

the participants under the hospital diet, then placed into sterile cryotube and frozen
at -80°C refrigerator before further use.

Whole blood samples for biochemical measurements were collected after at least 10-127 hour fasting period. The measurements of fasting glucose, lactate dehydrogenase, 128 creatine kinase, c-reactive protein, serum alanine aminotransferase, aspartate 129 aminotransferase, glutathione S-transferase, creatinine, glycated serum protein, high-130 density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoproteins, 131 lipoprotein, and serum amyloid A were performed by an autoanalyzer (AU5800, 132 133 Beckmancoulter). HbA1C was measured by an automated clinical analyzer (H100plus, Lifotronic). Plasma brain natriuretic peptide level was measured by a full-automatic 134 chemiluminescence immunoassay analyzer (Cobas e602, Roche). Plasma troponin 135 was measured using an autoanalyzer (DXI800, Beckmancoulter). Urine samples were 136 137 analyzed by urine sediment analyzer (UF-5000, Sysmex).

138 Pseudo-targeted metabolomics profiling and preprocessing

Metabolomic profiling was performed utilizing the CalOmics metabolomics platform at Calibra Lab, affiliated with DIAN Diagnostics. The analytical instrumentation comprised an ACQUITY 2D UPLC system (Waters, Milford, MA, USA) coupled with a Q Exactive (QE) hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, San Jose, USA). Metabolites were analyzed, based on the chemical properties of the serum metabolites, utilizing both polar ionic and lipid modes.

Sample preparation involved the extraction of metabolites using a methanol solvent at a 1:4 ratio. Following extraction, mixtures were shaked for three minutes and subsequently subjected to centrifugation at 4000 \times g for 10 minutes at 20°C to precipitate proteins. The resulting 100 µL aliquots of supernatant were transferred onto sample plates, dried under a stream of nitrogen, and reconstituted in appropriate solvents for injection into the UPLC-MS/MS system.

151 The QE mass spectrometer settings included a mass resolution of 35,000 and a scan 152 range from 70 to 1000 m/z. For the first UPLC-MS/MS method, the instrument

operated in positive electrospray ionization (ESI) mode using a C18 reverse-phase 153 UPLC column (UPLC BEH C18, 2.1x100 mm, 1.7 µm; Waters). The mobile phases 154 consisted of water (A) and methanol (B) with 6.5 mM ammonium bicarbonate at pH 155 156 8 for gradient elution. The third method similarly employed the C18 reverse-phase column in ESI positive mode, but used a mobile phase of water (A) and a mixture of 157 methanol, acetonitrile, and water (B) containing 0.05% perfluoropentanoic acid 158 (PFPA) and 0.01% formic acid (FA). In the fourth method, the system was operated in 159 negative ESI mode with a hydrophilic interaction liquid chromatography (HILIC) 160 161 column (UPLC BEH Amide, 2.1x150 mm, 1.7 μ m; Waters), and the mobile phases 162 were water (A) and acetonitrile (B) containing 10 mM ammonium formate.

163 Following the preprocessing of raw data and rigorous data quality control 164 assessments, ion peaks were extracted employing proprietary in-house information technology hardware and software systems. Metabolites were subsequently 165 identified through querying a bespoke library, which was compiled using pure 166 standards sourced from commercial providers or other available channels. The 167 identification protocol for metabolites within the samples was stringent, requiring a 168 precise match across three specific criteria when compared to the library entries: a 169 narrow retention index window, mass accuracy within a 10 ppm deviation, and 170 tandem mass spectrometry (MS/MS) spectra that exhibit high scores in both forward 171 and reverse searches. Quantification of each metabolite was achieved by calculating 172 the peak area using the area-under-the-curve (AUC) method. This approach ensures 173 174 accurate measurement of metabolite concentrations within the samples.

Before statistical analysis, raw peak areas were normalized to adjust for system fluctuation among different run days. The normalized peak areas were then logtransformed (log2) to reduce data distribution skewness and be in approximate normal distribution (Gaussian distribution). Missing values in peak area matrix were imputed by using the minimal detection value of a metabolite among all tested samples.

181 DNA extraction and library construction of fecal samples

Deoxyribonucleic acid (DNA) was extracted from fecal samples utilizing the cetyltrimethylammonium bromide (CTAB) method. Control samples included unused swabs which were processed identically through the DNA extraction protocol to ensure absence of DNA amplification products. The resultant DNA was eluted in 50 μl of elution buffer, following a modified protocol provided by QIAGEN, and preserved at -80°C for subsequent analyses.

For polymerase chain reaction (PCR) analysis, the samples were processed at LC-BIO Technologies Co., Hangzhou, China. The construction of the DNA library was accomplished using the TruSeq Nano DNA LT Library Preparation Kit (FC-121-4001). Fragmentation of the DNA was performed using dsDNA Fragmentase (NEB, M0348S) at 37°C for 30 minutes. This step produced blunt-ended DNA fragments via a combination of fill-in reactions and exonuclease activity. Size selection was then conducted using the sample purification beads provided in the kit.

To prepare the DNA fragments for adapter ligation, an adenine (A) base was added to the blunt ends of each strand. Each adapter, designed with a thymine (T) base overhang, facilitates the ligation to the A-tailed DNA fragments. These adapters are crucial as they contain necessary sites for the hybridization of sequencing primers, enabling single, paired-end, and indexed sequencing reads.

Ligation involved either single or dual index adapters, and the products were subsequently amplified via PCR. The amplification parameters included an initial denaturation at 95°C for 3 minutes, followed by 8 cycles of denaturation at 98°C for 15 seconds, annealing at 60°C for 15 seconds, extension at 72°C for 30 seconds, and a final extension at 72°C for 5 minutes. This process prepares the library for highthroughput sequencing analyses.

206 Metagenomic sequencing data processing

Raw sequencing data were processed to generate clean reads suitable for downstream analyses. Initially, sequencing adapters were excised from the reads using Cutadapt (version 1.9). Subsequently, low-quality reads were trimmed using fqtrim (version 0.94), which employs a sliding-window algorithm. Reads were then

aligned to the host genome using Bowtie2 (version 2.2.0) to eliminate host-derived 211 sequences. Following the quality filtering, the remaining reads were assembled de 212 novo using IDBA-UD (version 1.1.1) to construct individual metagenomes for each 213 214 sample. Predictions of coding regions (CDS) within the metagenomic contigs were performed by MetaGeneMark (version 3.26). The CDS sequences across all samples 215 were clustered using CD-HIT (version 4.6.1) to generate a set of unigenes. Unigene 216 abundance in each sample was estimated using transcripts per million (TPM) based 217 on read alignment performed again with Bowtie2 (version 2.2.0). Taxonomic 218 219 classification of the unigenes was achieved by aligning them to the NCBI non-220 redundant (NR) database using DIAMOND (version 0.9.14). The taxonomic 221 annotations and abundance profiles of these unigenes were utilized to conduct differential analysis at both taxonomic and gene-specific levels. Enterotypes profiling 222 was performed using pipeline as previously demonstrated (18). Phage-inclusive 223 224 metagenomics profiling was conducted with Phanta.

225 **Profiling of bacterial structural variations**

Prior to the structural variations (SVs) classification, the iterative coverage-based 226 read assignment pipeline was used to precisely reassign the ambiguous reads to the 227 228 most likely reference(19,20). The reference genomes given in the proGenomes database (http://progenomes1.embl.de/) were concatenated, separated into 229 230 genomic 1-kbp bins, and used for the detection of highly variable genomic variations. The SGV-Finder pipeline(19) was used to identify SVs that fall into one of three 231 categories: (1) variable SVs, or vSVs, (2) deletion SVs, or dSVs; the presence or 232 absence of a specific genomic segment was maintained; or (3) deletion SVs, or dSVs, 233 with deletion percentages of >75% (this genomic segment was excluded from the 234 analysis). All bacterial species with SV calling were found in at least 10% of all 235 samples and were used in the analysis that followed. 236

237 Molecular docking simulation

The crystal structures of several human receptors were obtained from the RCSB Protein Data Bank (<u>https://www.rcsb.org/</u>). These include the free fatty acid receptor

1 (GPR40, PDB ID: 5TZY), the thromboxane A2 receptor (TXA2, PDB ID: 6IIV), and the 240 P2Y purinoceptors 1 and 12 (PDB IDs: 4XNW and 7PP1, respectively). Subsequent to 241 242 download, water molecules and co-crystallized ligands were removed from the .pdb files to prepare the proteins for molecular docking studies. For the docking 243 simulations, the receptor structures were prepared by adding polar hydrogen atoms 244 and computing partial charges using the Kollman and Gasteiger methods. These 245 modifications were performed using AutoDock Tools (version 1.5.638). The prepared 246 247 structures of both ligands and receptors were then saved in .pdbgt format, facilitating their use in subsequent molecular docking procedures. The molecular 248 docking studies were performed using the open-source software AutoDock Vina 249 (version 1.1.2) (21) investigate the interactions between AMI-associated long-chain 250 fatty acids (LCFAs) and selected receptors involved in platelet aggregation. 251 Adjustments to the grid box allowed the AutoDock algorithm to predict ligand 252 conformations within the receptor binding sites and evaluate them using scoring 253 functions (22), with the grid spacing set at 1 Å. The three-dimensional interactions 254 between the selected receptors and long-chain fatty acids (LCFAs) were analyzed and 255 visualized using the PyMOL Molecular Graphics System (version 2.5.0), an open-256 source platform. Subsequently, AutoDock version 4.2 was employed to predict the 257 258 binding affinities between various ligands and the selected receptors, providing quantitative insights into the potential binding interactions (23). 259

260 Thrombogenic effect of LCFAs on isolated human platelets

Fresh platelets were obtained from normal human volunteers without any 261 antiplatelet or anticoagulant drugs being used within 2 weeks. Whole blood was 262 collected from the peripheral vein of healthy volunteers into 0.1 vol of ACD buffer (75 263 mM sodium citrate, 39 mM citric acid, and 135 mM dextrose, pH 6.5). Diluted whole 264 265 blood was centrifuged at 1500g for 20 minutes at 25 °C, and platelet-rich plasma 266 (PRP) was collected into a fresh tube. Then we diluted PRP in ACD buffer, and centrifuged it at 800g for 10 minutes at 25°C. The platelet pellet was then 267 resuspended in Tyrode's buffer (137 mM NaCl, 2 mM KCl, 0.34 mM Na₂HPO₄, 12 mM 268

NaHCO₃, 1 mM MgCl₂, 5.5 mM glucose, 5 mM HEPES, and 0.35% BSA, pH 6.5) at 10^9 platelets/mL, and kept at 23 °C for up to 4 h before use.

Incubations of washed human platelets with fatty acids were done either in pH 6.5
phosphate buffer or in "pH 7.4 Tris buffer" (15.4 mM Tris-Cl, pH 7.4; 140 mM NaCl,
5.6 mM glucose(24)). Candidate LCFAs to be tested were chosen according to the
results shown in Figure 2a. Then individual LCFA was diluted to specific concentration
(1 mM, 2.5mM, 5mM and 10mM) by bovine serum albumin solution (BSA),
respectively. Platelet aggregations were measured using a lumi-aggregometer
(AG800, Shandong, China) at 37 °C under stirring at 1200 rpm.

278 Statistical analysis

In this study, no data were excluded before the statistical analysis. As the study is 279 observational, no allocation or randomization was used. This study includes all 280 available samples (n = 56) of patients with AMI and healthy individuals. Although 281 282 sample sizes were not predetermined using statistical methods, our sample sizes are comparable to those published earlier(25,26). The distribution of samples among 283 metagenomics and metabolomics batches was random. During the data collecting 284 phases of the metagenomic, biochemical, and metabolomics, researchers were 285 blinded to the group allocation. 286

All statistical analyses were performed with R (version 4.2.3). Significantly differed 287 metabolites or taxa between AMI and control groups were found by parametric 288 (student's *t*-test) or non-parametric (Wilcox's rank test) statistical methods. 289 Multivariate analysis approaches including principal component analysis (PCA), 290 291 principal coordinate analysis (PCoA), and random forest (RF) were also conducted. Permutational multivariate ANOVA (PERMANOVA) was performed to determine the 292 differences in structures of global microbiome and LCFAs between AMI patients and 293 controls by using *vegan* (v2.6-4) package. The association analysis between omics 294 features were performed by spearman correlation using *cor.test* base command. 295 Least absolute shrinkage and selection operator (LASSO) regression model was built 296 by using *qlmnet* (v4.1-7) package. Unless otherwise stated, all p values were 297

corrected using the Benjamini-Hochberg method andz Padj < 0.05 was considered
statistically significant.

300

301 **Results**

302 Plasma metabolome and gut microbiome from a deeply phenotyped eAMI cohort

We profiled plasma samples collected from 30 early acute myocardial infarction 303 (eAMI) patients (within 12 hours in emergency) and 26 age- and gender-matched 304 healthy controls (HC), using mass spectrometry. For these participants, we also 305 306 characterized gut microbiota by performing shotgun metagenomic sequencing of fecal samples. In addition, as shown in **Table 1**, it is important to note that HC in this 307 study had no obstructions in in any of their coronary arteries, which was validated by 308 coronary angiography, in addition to having bioclinical characteristics that were 309 within heathy thresholds. As expected, eAMI patients are distinct from HC with 310 elevated troponin, pro-BNP, and creatine kinase (p values < 1.0e-03) despite 311 matching for age, sex, BMI and T2D status. Also, eAMI patients display increased 312 313 inflammatory markers including C-reactive protein, white blood cells, neutrophils, 314 and lymphocytes (p values < 1.0e-03).

315 A pseudo-targeted metabolomics platform was used to profile 926 identified 316 metabolites, as well as 26 partially characterized features (Table S1). Metabolites belonged to diverse biochemical classes, including lipids, amino acids, xenobiotics, 317 nucleotides, and carbohydrates (Figure S2a). Most metabolites (877) were measured 318 in over 50% of the cohort, and 555 metabolites were present in all samples (Figure 319 S2b). All the samples were randomly injected and median of RSDs for the internal 320 standards used in the quality control samples is 2.78%, demonstrating the high 321 quality of metabolomics data. 322

Bacterial DNA was extracted from fecal samples, sequenced on the Illumina platform, and a total of 402 Gb 150-bp paired-end reads were generated, with an average of 47.70 ± 5.98 (s.d.) million reads per sample (**Table S2**). For each sample, a majority of

high-quality sequencing reads (69.03–97.24%) were *de novo* assembled into long contigs or scaffolds, which were used for gene prediction, taxonomic classification,

and profiling of structural variations (SVs) in bacterial genomes.

329 LCFAs dominate the metabolome perturbations in eAMI plasma

330 Principal component analysis of the 952 measured compounds is used in Figure 1a to 331 show the remarkable differences in the global plasma metabolome of eAMI patients compared to HC subjects and individual contrasted metabolites are shown in Figure 332 **S3**. To characterize the dysregulated metabolic pathways in patients with eAMI, we 333 performed KEGG pathway enrichment analysis of the differential metabolites and 334 observed that biosynthesis of unsaturated fatty acids (FA) was the most significantly 335 disrupted in eAMI patients (Figure 1b). Moreover, we found that across the eAMI and 336 HC groups, the 32 LCFAs species (saturated, monounsaturated, and polyunsaturated) 337 338 showed considerable inter-individual heterogeneity (Figure 1c). Plasma LCFAs composition also displayed a significant variation between the two groups 339 (permutational multivariate analysis of variance (PERMANOVA), p < 1.0e-03; Figure 340 1d), with 28 upregulated LCFAs between patients with eAMI and HC as demonstrated 341 in the volcano plot (Figure 1e). 342

Thereafter, we divided our cohort into a training group (comprising 70% of the 343 subjects) and a test set (comprising 30% of the subjects) to identify diagnostic 344 biomarkers for differentiating HC and patients with eAMI. The training dataset was 345 utilized to perform feature selection using LCFAs in plasma, and the selected features 346 347 were then used to create a random forests classifier (Figure 2a). With an area under the receiver operating characteristic curve (AUC) of 0.927 in the training set, the 348 random forests model by a biomarker panel of 14 LCFAs (Figure 2b) allowed 349 differentiation between HC and eAMI groups (Figure 2c). The created classifier was 350 351 subsequently used in testing dataset to estimate independent performance of our model, which had an AUC of 1 (Figure 2d). Overall, these findings reveal the 352 differences of LCFAs alteration is dominant in metabolome perturbations of patients 353 with eAMI and demonstrate LCFAs may allow to discover more potent biomarkers, 354 355 making the diagnosis of eAMI more accessible.

356 Alterations in gut microbiome is associated with the LCFA dysmetabolism in eAMI

We next explored the underlying factors that regulate LCFA metabolism by factor 357 analysis, where we found age, sex, and body mass index could only account for up to 358 359 10% of the variance in LCFA proportion (Figure 3a). This indicates that a large 360 proportion of LCFA variation remains unexplained and may be attributed to other variables, for example, gut microbial factors. Consistent to previous reports(12), we 361 identified that eAMI gut microbiome is not only distinct from but also more 362 heterogenous than that of HC subjects (Figure S4). Furthermore, we found eAMI gut 363 microbiome is marked by an enrichment in the Bacterides2 enterotype (P_{Fisher's exact} 364 test = 2.3e-02) with a slight depletion in Bacteroides1 enterotype ($P_{\text{Fisher's exact test}} = 3.1e$ -365 01, Figure 3b), which always represents a marker suggesting a high risk of metabolic 366 367 disorders(27).

368 To furtherly understand if gut microbiome is involved in the regulation of LCFAs during the onset of eAMI, we performed a least absolute shrinkage and selection 369 operator (LASSO) regression model to compute the variance in each of the detected 370 LCFAs that can be explained by gut microbiome. Intriguingly, gut microbiome at 371 species level explains up to 70% of the variance in LCFAs composition in this cohort 372 (Figure 3c). We next sought to identify the potential bacterial taxa that associate with 373 the LCFAs by spearman correlation. At genus level, Mycobacteroides, Thermus, and 374 Anaerostipes are inversely linked to LCFAs (Figure S5). As shown in Figure 3d, we 375 376 found Streptococcus species were negatively correlated with omega-3 polyunsaturated FAs including FFA 18:4 (n-3), FFA 18:3 (n-3 or -6), and FFA 22:5 (n-3), 377 which were considered as cardioprotective compounds. Meanwhile, the 378 Streptococcus species were found to be positively correlated with omega-6 379 polyunsaturated FAs and saturated LCFAs. Moreover, we discovered that the eAMI 380 gut virome exhibits a decrease in Vibrio phage (Figure 4a) but enrichments in 381 Streptococcus phage PH10 and Streptococcus phage SM1 (Figure 4b), both of which 382 383 have known hosts that are *Streptococcus* species. *Streptococcus* bacterial species predominate in the eAMI gut microbiome (Figure S4a), although the mechanism 384 underpinning this dominance is unclear. Nonetheless, the abundance in temperate 385 lysogenic Streptococcus phages may provide some justification. Additionally, the total 386

number of virulent phages found in the eAMI gut microbiome is higher than in the
healthy controls (Figure 4c). The ratio of virulent to temperate phages is also greater
in the eAMI group compared to the HC group.

390 Gut bacterial structural variants profiling in eAMI

391 Structural variations (SVs) in bacterial genomes can disrupt gene function, thereby 392 influencing the interactions between bacteria and their hosts (25). As a result, significant phenotypic and functional alterations within the gut microbiome of 393 patients with early acute myocardial infarction (eAMI) may arise from differences in 394 the presence or levels of SVs among genetically similar bacterial strains. Here, we 395 profiled SVs in all samples and identified 4,234 deletion SVs and 1,948 variable SVs 396 across 47 bacterial species (Figures 5a and 5b). For some species, we observed 397 considerable differences in copy number variation. We identified 87 deletion SVs and 398 399 18 variable SVs in *Bacteroides uniformis* across 134 individuals, 78 deletions and 15 variable SVs in *Faecalibacterium prausnitzii* in 124 individuals, and 110 deletion SVs 400 and 55 variable SVs in *Parabacteroides distasonis* in 121 individuals. For the archaeal 401 microbiota, we only identified SVs in Methanobrevibacter smithii in 13 individuals 402 (Figures 5a). To explore potential differences in bacterial genetics, we further 403 computed the Canberra distance of bacterial SV profiles between eAMI versus HC 404 (Figure 5c). eAMI and HC samples were significantly different in the beta-diversity of 405 406 SV composition (P_{Wilcoxon} = 1.4e-05) and composition of bacterial genetics in eAMI 407 individuals has less heterogeneity than that of HC subjects.

408 Bacterial genetics associate to LCFAs dysmetabolism in eAMI

Exploring relationships between gut bacterial SVs and plasma LCFAs, we found that bacterial SVs were significantly related to LCFAs (**Figure 5d**). As a particularly notable example, in the association analysis between SVs in the *Alistipes shahii* genome and plasma LCFAs profile, we found that a 3-kbp deletion (*A. shahii*:575-578) was directly associated with FFA 22:4 and FFA 14:1 but inversely linked to FFA 16:0, indicating that this deletion SV may be involved in the regulation of LCFAs metabolism in eAMI (**Figure 5e**). According to gene analysis, the beginning of this specific genomic region

in A. shahii encodes a 3-oxoacyl-[acyl-carrier protein] reductase (FabG, Figure 5f), 416 which is an enzyme catalyzes the NADPH-dependent reduction of beta-ketoacyl-ACP 417 substrates to beta-hydroxyacyl-ACP products, the first reductive step in the 418 419 elongation cycle of fatty acid biosynthesis. This deletion region is more prevalent in eAMI group compared to HC gut microbiome (Figure 5g). In accordance with the 420 association analysis, we furtherly found that individuals with A. shahii genomes 421 harboring this deletion have higher plasma FFA 22:4 and FFA 14:1 but lower level of 422 FFA 16:0, compared to participants without this 3-kbp deletion in A. shahii genome 423 424 (Figure 5h).

425 Molecular docking and thrombosis in human platelets support the thrombogenic 426 effect of eAMI-associated LCFAs

427 We extended our work to *in silico* molecular docking to investigate the molecular 428 connections that control thrombosis. Four canonical receptors that are involved in platelet aggregation—free fatty acid receptor 1 (GPR40), thromboxane A2 receptor 429 (TXA2), P2Y purinoceptor 1 (P2Y1), and P2Y purinoceptor 12 (P2Y12)—were taken 430 into account as binding receptors in the molecular docking models in addition to the 431 28 eAMI-associated LCFAs as binding ligands. As shown in Figure 6a, we selected the 432 first-ranked complex models between the various LCFAs and these four receptors. 433 Interestingly, the molecular docking models estimated substantial interactions 434 435 between eAMI-associated LCFAs and four selected receptors, with binding affinity ranging from -5.7 to -9.1 kJ/mol (Figure 5a). Representative docking results for 436 bindings between the chosen receptors and omega-3, -6, and -9 polyunsaturated FAs 437 are displayed in Figure 6b. 438

Then, using *in vitro* human platelet anticoagulation assay, we aimed to experimentally validate the thrombogenic effects of eAMI-associated LCFAs. As shown in **Figure 6c**, we found omega-6 LCFAs significantly stimulate platelet aggregation at physiological concentrations (1 mM to 10 mM). As a non-ignorable example, FFA 19:1 (n-9), as a non-omega-6 LCFA, also causes strong thrombosis in human platelet (**Figure 6d**), while the mechanistic understanding behind this finding remains unknown. Our results imply suggest that eAMI-associated LCFAs may

possess potent thrombogenic functionality, making it fair to assume that they play asignificant role in host cardiometabolic health.

448 **Discussion**

The factors triggering the onset of AMI and the precise indicators of eAMI remain unclear. However, the application of plasma metabolomics provides valuable insights into the search for accurate diagnostic markers for complex conditions such as AMI. Additionally, comprehensive multi-omics profiling plays a crucial role in unraveling the underlying mechanisms responsible for AMI. Together, these approaches shed light on both diagnostic advancements and a deeper dissection disentangling the complexity of eAMI.

By plasma metabolomics profiling, we found that in patients with eAMI, there was a 456 remarkable increase in 28 LCFAs dominating the altered eAMI metabolome. These 457 LCFAs encompassed a variety of saturated, monounsaturated, and polyunsaturated 458 459 types. When investigating the etiology of LCFA dysmetabolism in eAMI, we initially 460 examined its correlation with conventional AMI risk factors including age, sex, body mass index, and potentially diabetes. However, these factors alone could only explain 461 a maximum of 10% of the variation observed in LCFA proportions. This raises the 462 question of what accounts for the remaining 90% of LCFA variation. To this end, we 463 turned our attention to profiling the gut microbiota, as it is widely recognized for its 464 potential role in regulating the metabolome. The LASSO regression model allows us 465 to examine various factors influencing LCFA composition and reveals gut microbiome 466 467 at the species level accounted for up to 70% of the observed variance in the 468 composition of LCFAs. This finding suggests a significant association between the gut microbiome and the alterations in LCFA levels. 469

To gain mechanistic insights behind the gut microbiome-LCFA interactions, we associated bacterial SVs with LCFAs and observed significant relations. Of specific interest is a 3-kbp deletion (*A. shahii*: 575-578) representing *FabG* gene, a key enzyme in reduction step of elongation cycle in fatty acid biosynthesis, which is more prevalent in eAMI gut microbiome, resulting in a relatively higher plasma FFA 22:4

and FFA 14:1 in eAMI patients. Others have already reported the increase of 475 intracolonic saturated LCFAs positively associated with elevated abundances of 476 Prevotella, Lactobacillus, and Alistipes (28). Additionally, the presence of A. shahii was 477 478 also shown to strengthen the positive associations of red meat intake with 479 trimethylamine N-oxide (TMAO) concentrations levels(29), while increased TMAO levels enhances platelet hyperreactivity and thrombosis risk(30), and is associated 480 with an increased risk of incident major adverse cardiovascular events(31). These 481 findings support that in addition to short-chain fatty acids – which are known gut 482 483 microbial products – disturbances in the gut microbiota also contribute significantly 484 to the variation in plasma LCFAs during eAMI.

485 Indeed, the question arises whether the elevated levels of LCFA in eAMI are merely a 486 marker or if they hold pathophysiological significance. Considering that platelet activation is a distinct pathophysiological characteristic of eAMI, we sought to 487 explore the impact of eAMI-associated LCFA on circulating platelet activation. As 488 expected, we found a majority of omega-6 LCFAs rather than omega-3 LCFAs dose-489 dependently stimulate platelet aggregation. A role for omega-3 polyunsaturated fatty 490 acids (PUFA) supplementation to achieve cardioprotective effects has also been 491 shown by attenuating platelet function(32), aligning with our findings. To date, there 492 493 is limited conclusive evidence regarding the effect of LCFAs on platelet activation, except for arachidonic acid (FFA 20:4 (n-6)), a well-known LCFA that activates 494 platelets. However, our study has yielded intriguing results. We have discovered that 495 both FFA 19:1 (n-9) (also known as 10-nonadecenoic acid, HMDB0013622) and FFA 496 22:4 (n-6) (Adrenic acid, HMDB0002226) can significantly induce human platelet 497 aggregation to a similar degree as arachidonic acid (FFA 20:4 (n-6), see Figure S6). 498 Notably, FFA 22:4 (n-6) can be synthesized from arachidonic acid (FFA 20:4 (n-6)), 499 500 which, in turn, can be elongated from FFA 18:2 (n-6), also known as linoleic acid. These conversions and interactions among omega-6 PUFAs provide a potential 501 mechanism for their role in activating platelets. 502

503 Consistent with previous reports(33), the outcome of our *in vitro* experiments 504 supports many eAMI-associated LCFAs, especially omega-6 PUFAs can promote 505 platelet aggregation even in normal physiological concentration (1-5 mM). However,

lots of epidemiological investigation has found higher intakes of omega-6 PUFA 506 appear to be safe and may be even more beneficial, hence the AHA supports an 507 omega-6 PUFA intake of at least 5% to 10% of energy for dietary recommendations of 508 509 coronary heart disease(34). In another prospective analyses, higher in vivo circulating and tissue levels of LA and possibly AA were associated with lower risk of major 510 cardiovascular events(35). Intriguingly, omega-6 PUFA, dihomo-y-linolenic acid (FFA 511 20:3 (n-6)) has been shown to play a role in inhibiting platelet aggregation ex vivo, via 512 COX-1-derived prostanoid metabolites(36). Therefore, it still has the overwhelming 513 514 controversial data on potential effects of omega-6 PUFAs on platelet function.

While our study offered valuable multi-omics insights into a cohort of patients with 515 516 eAMI, uncovering the association between gut dysbiosis and plasma metabolomic perturbations characterized by the notable enrichment of LCFAs, it is important to 517 acknowledge certain limitations in our present study. Firstly, we propose that 518 intestinal microbial disturbances are significantly associated with fatty acid 519 dysmetabolism based on cross-sectional correlation analysis. However, the causal 520 relationship between gut microbiota dysbiosis and altered FA metabolism remains 521 unclear and requires confirmation in prospective cohorts. Secondly, while platelet 522 activation is a characteristic feature of eAMI, the specific in vivo role of LCFAs is still 523 524 not well understood, and there is ongoing debate regarding the effect of ω -6 LCFAs on platelet function. Thirdly, we still don't know the direct or indirect effect of gut 525 microbiota dysbiosis on platelet activation, as well the underlying mechanism 526 responsible for it, despite there is report TMAO(30) 527 on and phenylacetylglutamine(37) contributing to platelet hyperreactivity and enhanced 528 thrombosis potential. Fourthly, although all participants followed a standardized in-529 hospital diet and stool samples were collected shortly after hospitalization, the 530 531 potential influence of pre-hospital diet on intestinal microbiome and plasma metabolome profiling, as well as their interaction, cannot be completely ruled out. 532 Finally, due to the limitations of sample size and the specific population background 533 included in this study, the conclusions drawn from our findings should be furtherly 534 validated through large-scale, prospective studies involving diverse regional 535 populations. 536

537 Data availability

The metadata are available under restricted access due to participant consent and privacy regulations of this cohort, access can be obtained by request to the corresponding author. Access to the metagenomics and metabolomics data may be granted for statistical and scientific research with approval from the corresponding author (Hanbin Cui: hbcui nbdyyy@outlook.com).

543 Code availability

544 Scripts associated with the data analysis and visualization are available at 545 https://github.com/fjw536/AMI gut microbiome.

546 Acknowledgements

547 We thank the study participants and nurses for their contributions to the project. We 548 gratefully acknowledge colleagues at Lianchuan biotechnology for Metagenomics 549 sequencing analysis of gut microbiota, and Dl'AN Diagnostics, Key Laboratory of 550 Digital Technology in Medical Diagnostics of Zhejiang Province for plasma 551 metabolomics profilling, data analysis and discussions.

552 Author contributions

Y.F., J.Y. and H.C. conceived and designed the study. J.Y., F.H., K.H., T.H., H.M., P.S. X.H.,
H.M., Z.L., R.Z., J.L., J.C., S.W., X.S., H.H., P.W., M.G., J.S., W.D., Y.W., H.Z., S.L., X.F.,
W.L., R.F., F.H. and X.C. were involved in the acquisition of samples and data. Y.F. and
Z.K. analyzed and interpreted the data. Y.F. and J.Y. drafted the work and H.C.
substantively revised it. All authors contributed to the article and approved the
submitted version.

559 **Competing interests**

560 All authors declare no competing interests in this study.

561 Funding

This research was supported by the Key research and development project of Zhejiang Province, China (no. 2021C03096), Major Project of Science and Technology Innovation 2025 in Ningbo, China (no. 2021Z134) and Ningbo Clinical Research Center for Cardiovascular Disease, Ningbo, China (no. 2022L001).

567 **Reference**

- DALYs GBD, Collaborators H. Global, regional, and national disability-adjusted life years
 (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries,
 1990-2013: quantifying the epidemiological transition. Lancet 2015;386:2145-91.
- Faxen J, Jernberg T, Hollenberg J, Gadler F, Herlitz J, Szummer K. Incidence and Predictors of
 Out-of-Hospital Cardiac Arrest Within 90 Days After Myocardial Infarction. J Am Coll Cardiol
 2020;76:2926-2936.
- 5743.Gong W, Yan Y, Wang X et al. Risk Factors for In-Hospital Cardiac Arrest in Patients With ST-575Segment Elevation Myocardial Infarction. J Am Coll Cardiol 2022;80:1788-1798.
- Anderson JL, Morrow DA. Acute Myocardial Infarction. The New England journal of medicine
 2017;376:2053-2064.
- 578 5. Crea F, Libby P. Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision 579 Treatment. Circulation 2017;136:1155-1166.
- 5806.Maier W, Altwegg LA, Corti R et al. Inflammatory markers at the site of ruptured plaque in581acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but582decreased C-reactive protein. Circulation 2005;111:1355-61.
- 5837.Granger CB, Kochar A. Understanding and Targeting Inflammation in Acute Myocardial584Infarction: An Elusive Goal. J Am Coll Cardiol 2018;72:199-201.
- 5858.Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated586gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-31.
- 587 9. Karlsson FH, Tremaroli V, Nookaew I et al. Gut metagenome in European women with normal,
 588 impaired and diabetic glucose control. Nature 2013;498:99-103.
- 58910.Jonsson AL, Backhed F. Role of gut microbiota in atherosclerosis. Nature reviews Cardiology5902017;14:79-87.
- 59111.Barrington WT, Lusis AJ. Atherosclerosis: Association between the gut microbiome and592atherosclerosis. Nature reviews Cardiology 2017;14:699-700.
- 593 12. Jie Z, Xia H, Zhong SL et al. The gut microbiome in atherosclerotic cardiovascular disease.
 594 Nature communications 2017;8:845.
- 59513.Karlsson FH, Fak F, Nookaew I et al. Symptomatic atherosclerosis is associated with an altered596gut metagenome. Nature communications 2012;3:1245.
- 59714.Fan Y, Ying J, Ma H, Cui H. Microbiota-related metabolites fueling the understanding of598ischemic heart disease. iMeta 2023;2:e94.
- 59915.Kelly TN, Bazzano LA, Ajami NJ et al. Gut Microbiome Associates With Lifetime Cardiovascular600Disease Risk Profile Among Bogalusa Heart Study Participants. Circulation research6012016;119:956-964.
- 60216.Liu M, Wang M, Peng T et al. Gut-microbiome-based predictive model for ST-elevation603myocardial infarction in young male patients. Frontiers in microbiology 2022;13:1031878.
- 604 17. Gulati M, Levy PD, Mukherjee D et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR
 605 Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of
 606 Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am
 607 Coll Cardiol 2021;78:e187-e285.
- 60818.Vieira-Silva S, Falony G, Belda E et al. Statin therapy is associated with lower prevalence of gut609microbiota dysbiosis. Nature 2020;581:310-315.

- 610 19. Zeevi D, Korem T, Godneva A et al. Structural variation in the gut microbiome associates with
 611 host health. Nature 2019;568:43-48.
- 612 20. Wang D, Doestzada M, Chen L et al. Characterization of gut microbial structural variations as
 613 determinants of human bile acid metabolism. Cell Host Microbe 2021;29.
- Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new
 scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455461.
- 617 22. Pahonţu E, Proks M, Shova S et al. Synthesis, characterization, molecular docking studies and
 618 in vitro screening of new metal complexes with Schiff base as antimicrobial and
 619 antiproliferative agents. Appl Organometal Chem 2019;33:e5185.
- 620 23. Morris GM, Huey R, Lindstrom W et al. AutoDock4 and AutoDockTools4: Automated docking
 621 with selective receptor flexibility. J Comput Chem 2009;30:2785-2791.
- 622 24. Neufeld EJ, Wilson DB, Sprecher H, Majerus PW. High affinity esterification of eicosanoid
 623 precursor fatty acids by platelets. J Clin Invest 1983;72:214-220.
- Fan Y, Støving RK, Berreira Ibraim S et al. The gut microbiota contributes to the pathogenesis
 of anorexia nervosa in humans and mice. Nat Microbiol 2023;8:787-802.
- 62626.Kindschuh WF, Baldini F, Liu MC et al. Preterm birth is associated with xenobiotics and627predicted by the vaginal metabolome. Nat Microbiol 2023;8:246-259.
- Vieira-Silva S, Falony G, Belda E et al. Statin therapy is associated with lower prevalence of gut
 microbiota dysbiosis. Nature 2020;581:310-315.
- 28. Zhao L, Huang Y, Lu L et al. Saturated long-chain fatty acid-producing bacteria contribute to
 enhanced colonic motility in rats. Microbiome 2018;6:107.
- 632 29. Li J, Li Y, Ivey KL et al. Interplay between diet and gut microbiome, and circulating
 633 concentrations of trimethylamine N-oxide: findings from a longitudinal cohort of US men. Gut
 634 2022;71:724-733.
- 63530.Zhu W, Gregory JC, Org E et al. Gut Microbial Metabolite TMAO Enhances Platelet636Hyperreactivity and Thrombosis Risk. Cell 2016;165:111-124.
- 637 31. Tang WH, Wang Z, Levison BS et al. Intestinal microbial metabolism of phosphatidylcholine
 638 and cardiovascular risk. The New England journal of medicine 2013;368:1575-84.
- Adili R, Hawley M, Holinstat M. Regulation of platelet function and thrombosis by omega-3
 and omega-6 polyunsaturated fatty acids. Prostaglandins Other Lipid Mediat 2018;139:10-18.
- 64133.Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Progress in lipid research6422008;47:147-55.
- 643 34. Harris WS, Mozaffarian D, Rimm E et al. Omega-6 fatty acids and risk for cardiovascular
 644 disease: a science advisory from the American Heart Association Nutrition Subcommittee of
 645 the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular
 646 Nursing; and Council on Epidemiology and Prevention. Circulation 2009;119:902-7.
- 64735.Marklund M, Wu JHY, Imamura F et al. Biomarkers of Dietary Omega-6 Fatty Acids and648Incident Cardiovascular Disease and Mortality. Circulation 2019;139:2422-2436.
- Section 36. Yeung J, Tourdot BE, Adili R et al. 12(S)-HETrE, a 12-Lipoxygenase Oxylipin of Dihomo-gammaLinolenic Acid, Inhibits Thrombosis via Galphas Signaling in Platelets. Arteriosclerosis,
 thrombosis, and vascular biology 2016;36:2068-77.
- Acts via Adrenergic Receptors. Cell 2020;180:862-877 e22.

654

655 Figure legends

Figure 1| Long-chain free fatty acids (LCFAs) dominate the metabolome alterations 656 in plasma of early acute myocardial infarction (eAMI) patients compared with 657 healthy control (HC) individuals. (a) Principal component (PC) analysis demonstrates 658 the remarkable metabolome alterations in eAMI patients compared with HC 659 individuals. (b) KEGG metabolic pathway enrichment of differential metabolites (FDR-660 adjusted p < 0.05) between eAMI and healthy controls. Fisher's exact test (one-side) 661 followed by FDR-adjusted p value was used and only pathways with FDR-adjusted p < 662 0.05 were shown. (c) Proportional structure of 32 detected LCFAs in plasma across all 663 samples of eAMI and HC individuals. LCFAs are colored by degree of saturation, 664 saturated LCFAs are colored in yellow, monounsaturated LCFAs are colored in red, 665 and polyunsaturated LCFAs are colored in blue. (d) Principal coordinate analysis 666 (PCoA) plot of the difference between eAMI and HC groups based on LCFAs 667 proportion profile. (e) Volcano plot of 952 detected metabolites by untargeted 668 metabolome profiling in eAMI patients and HC individuals. Red dots represent 669 significantly up-regulated (FDR-adjusted p < 0.05 and Cliff Delta > 0.4) metabolites in 670 eAMI plasma. Blue dots represent notably eAMI-depleted plasma metabolites (FDR-671 adjusted p < 0.05 and Cliff Delta < 0.4). Grey dots marked the unchanged 672 metabolites. Significantly altered LCFAs were labeled. The horizontal line represents 673 FDR cutoff of 0.05 and the vertical lines denote |Cliff Delta| > 0.4. 674

675 Figure 2 | Machine learning demonstrates long-chain free fatty acids (LCFAs) are potential diagnostic biomarkers for eAMI. (a) The top 20 most important LCFAs 676 reducing the variance (mean squared error (%IncMSE)) in classification of eAMI by 677 random forest model. %IncMSE denotes the increase in mean squared error of 678 predictions as a result of variable (LCFAs) being permuted. The training model was 679 constructed by proportional profile of 32 LCFAs in 39 training samples. (b) 680 Distribution of cross-validation error in random forest classification of eAMI patients 681 as the number of top ranking LCFAs increased. Red dot line marks the optimal 682 number of LCFAs (n = 14) for the classification of eAMI patients. (c and d) Receiver 683 operating characteristic (ROC) curve using the 14 LCFAs optimized by random forest 684

model for the (c) training and (d) test set (right panel, n = 17). Vertical heatmap in each panel denotes specificity for the ROC curve in c and d. AUC, area under the curve.

688 Figure 3 | Bacterial alterations characterize eAMI gut microbiome and greatly 689 explain the variance in plasma long-chain free fatty acids (LCFAs). (a) Density plot showing sample-wide distribution of (% of explained variances) intrinsic factors 690 (gender, age, and body mass index (BMI)) associated with the plasma concentrations 691 of LCFAs. (b) Bar plot demonstrates the variation of 32 LCFAs explained by identified 692 bacterial taxa at species level using LASSO regression. (c) Stacked bar plot shows the 693 prevalence of gut enterotypes in eAMI and control groups. (d) Circular heatmap 694 695 represents the correlation between LCFAs and gut bacterial species. Only association groups with FDR-adjusted p value of < 0.01 are colored in this plot. 696

697 Figure 4 | Alterations in viral gut microbiota between eAMI and HC groups. Box 698 plots showing the relative abundance of increased (a) and decreased (b) viral gut microbiota at species level in eAMI gut microbiome compared to that of HC group. 699 Differences in abundance were detected using MaAslin2. (c) Significant variations in 700 the abundance, abundance ratios, and counts of virulent and temperate phages 701 702 between the HC and eAMI groups. Significance was determined by Wilcoxon ranked sum test. For box plots in all panels, the vertical lines extend 1.5 times the 703 704 interguartile range (top and bottom borders of the box) and the median depicted by the horizontal line inside the box. 705

706 Figure 5 | Bacterial structural variations (SVs) links to long-chain free fatty acids profiles in acute myocardial infarction (AMI) patients. (a) Number of SVs of each 707 708 bacterial species in 56 study participants. (b) Pie chart showing the total identified 709 SVs numbers. (c) Boxplot of Canberra distance between samples within eAMI and healthy control (HC) groups based on SVs profile, significance is determined by two-710 sided Mann-Whitney U-test. (d) Chord diagram showing significant associations 711 between LCFAs and bacterial SVs. (e) Heatmap demonstrates the associations 712 713 between SVs of Alistipes shahii and LCFAs. Only significant correlations with FDRadjusted p value of < 0.01 are visualized. ++, FDR-adjusted p < 0.01, and +++, FDR-714

adjusted p < 0.001. (f) The deletion rate of the 3-kbp deletion harboring 3-oxoacyl-[acyl-carrier protein] reductase (FabG) in *Alistipes shahii*. (g) Stacking bar plot represents the prevalence of 3-kbp deletion SV of *Alistipes shahii* in eAMI and HC groups. (h) Relative abundance of LCFAs in individuals with and without the 3-kbp deletion SV of *Alistipes shahii*. **, p < 0.01, ***, p < 0.001 determined by two-sided Mann-Whitney *U*-test.

721 Figure 6 | Early acute myocardial infarction (eAMI)-associated long-chain free fatty acids (LCFAs) bind to thrombosis-related receptors and induce thrombosis in 722 723 human platelets. (a) Heatmap of binding energies between eAMI-associated LCFAs and thrombosis-related receptors through molecular docking. Bing affinities are 724 725 quantified at kJ/mol. (b) The representative AutoDock predicted binding conformation complex of LCFAs versus thrombosis-related receptors, within which 726 the receptors are depicted as cartoons and LCFAs as sticks. (c) The thrombogenic 727 impact of eAMI-associated LCFAs on human platelets is depicted in a heatmap. 728 Platelet aggregation ratios of > 10% and 10% are indicated by blue and grey, 729 respectively. (d) Representative platelet aggregation curves in a time interval of 300 730 seconds after the treatment of LCFAs at a concentration of 5 mM. Red dashed line 731 732 indicates 10% threshold.

733

734 Supplementary Figures

Figure S1 | Participant flow diagram. 123 suspected myocardial infarction patients
 were contacted, and 30 were eventually enrolled after screening.

Figure S2 | a, Distribution of measured metabolite super pathways of the 952 metabolites. b, Distribution of metabolite prevalence among the 56 samples. Blue distribution represents prevalence of all analyzed metabolites (n = 952). Numbers of metabolites that are present in more than 50% (n = 28) of the samples are indicated by dashed lines.

742 Figure S3 | Metabolic alterations in the plasma of eAMI patients. Heatmap of

contrasted metabolites in the plasma of healthy controls (HC) and eAMI patients.

Figure S4 | Alterations in bacterial gut microbiota in eAMI patients. a, Phylogenetic 744 tree of contrasted bacterial taxa between eAMI and HC bacterial gut microbiota. Taxa 745 746 colored in red and blue respectively represents increased and reduced taxa in eAMI 747 bacterial gut microbiota compared with HC group. **b**. Box plot (line, median; box, interquartile range (IQR); whiskers, $1.5 \times$ IQR) of β -diversity at bacterial species level 748 (Canberra distance) of eAMI (n = 30) and HC (n = 26) gut microbiota. Statistical 749 significances between two groups were determined by Wilcoxon rank-sum test (two-750 751 sided).

Figure S5 | Gut microbiome at genus level associate with long-chain fatty acids (LCFAs) metabolism. Circular heatmap represents the correlation between LCFAs and gut bacteria at genus level. Association groups with FDR-adjusted p value of < 0.05 are visualized in this plot.

Figure S6 | Thrombogenic effects of FFA 20:4 (arachidonic acid) in human platelets.
Platelet aggregation curves in a time interval of 300 seconds after the treatment of
FFA 20:4 at concentrations of 500 μM and 1 mM are given in (a) and (b), respectively.
Red dashed line indicates 10% threshold.

761 Table 1. Cohort characteristics

	eAMI , n = 30 ¹	Control , n = 26 ¹	p-value ²
Sub-classification			
Control	0 (0%)	26 (100%)	
NSTEMI	5 (17%)	0 (0%)	
STEMI	25 (83%)	0 (0%)	
Gender			0.051
Female	3 (10%)	8 (31%)	
Male	27 (90%)	18 (69%)	
Age (ys)	56 (46, 66)	59 (43 <i>,</i> 67)	>0.9
BMI (Kg/m²)	26.4 (22.9, 28.3)	24.4 (22.0, 26.3)	0.2
Smoking (n)	19 (63%)	4 (15%)	<0.001
Alcohol (n)	10 (33%)	2 (7.7%)	0.020
Hypertention (n)	22 (73%)	9 (35%)	0.004
Diabetes (n)	7 (23%)	4 (15%)	0.5
Other commorbidities (n)	4 (13%)	4 (15%)	>0.9
Antithrombiotic (n)	1 (3.3%)	3 (12%)	0.3
Statin (n)	1 (3.3%)	2 (7.7%)	0.6
Antiarrhythmic (n)	2 (6.7%)	2 (7.7%)	>0.9
Antidiabetic (n)	4 (13%)	2 (7.7%)	0.7
Antihypertensive (n)	12 (40%)	8 (31%)	0.5
PPI (n)	1 (3.3%)	1 (3.8%)	>0.9
Culprit vessel (n)	1 (0.070)	1 (0.070)	1 010
LM	1 (3.3%)	0 (0%)	>0.9
RCA	16 (53%)	0 (0%)	<0.001
LAD	22 (73%)	0 (0%)	<0.001
LCX	15 (50%)	0 (0%)	<0.001
Emergency troponin	0 (0, 4)	0 (0, 0)	0.5
(ng/mL)	0 (0, 4)	0 (0, 0)	0.5
Emergency BNP (ng/L)	0.97 (0.13, 2.05)	0.98 (0.98, 0.98)	>0.9
	37 (11, 99)	0 (0, 0)	<0.001
n-hospital troponin	07 (11,007	0 (0) 0)	
(ng/mL)			0.004
n-hospital Pro-BNP (ng/L)	395 (206, 1,039)	49 (17, 115)	<0.001
.DH (U/L)	0 (0, 473)	133 (133, 133)	0.7
Creatine kinase (U/L)	82 (40, 151)	2 (1, 3)	<0.001
CRP (mg/L)	0.9 (0.0, 3.6)	0.0 (0.0, 0.4)	0.003
WBC (*10^9/L)	12.4 (10.0, 13.3)	5.9 (4.9, 6.6)	< 0.001
Neutrophils (%)	79 (73, 86)	57 (49, 65)	< 0.001
ymphocyte (%)	14 (9, 17)	33 (23, 39)	<0.001
Hemoglobin (g/L)	145 (135, 155)	138 (129, 156)	0.5
RDW (%)	12.50 (12.20, 12.78)	12.50 (12.20,	0.7
		12.95)	.0.001
ALT (U/L)	50 (36, 63)	17 (13, 28)	< 0.001
AST (U/L)	252 (90, 358)	22 (18, 24)	< 0.001
GST/GLT	3.82 (2.66, 5.49)	1.18 (0.88, 1.38)	< 0.001
Creatinine (μmol/L)	73 (66, 88)	68 (55, 80)	0.068
BUN/creatinine	0.075 (0.053, 0.080)	0.070 (0.053,	0.7
		0.090)	o oc
Jric acid (µmol/L)	361 (301, 513)	325 (252, 384)	0.035
Fasting glucose (mmol/L)	5.9 (5.3, 7.9)	4.9 (4.4, 5.2)	<0.001
HbA1C (%)	5.85 (5.53, 6.35)	5.40 (0.00, 5.77)	0.003
GSP (mmol/L)	1.89 (1.72, 2.19)	1.71 (0.35, 1.86)	0.009
Total cholesterol (mmol/L)	5.32 (4.44, 5.93)	4.24 (3.33, 5.18)	0.002
Triglycerides (mmol/L)	1.44 (0.95, 2.79)	1.19 (0.76, 1.53)	0.042
HDL (mmol/L)	1.01 (0.90, 1.10)	1.00 (0.86, 1.24)	0.9


	eAMI , n = 30 ¹	Control , n = 26 ¹	p-value ²
LDL (mmol/L)	3.58 (2.92, 4.18)	2.81 (1.98, 3.16)	<0.001
apoB (g/L)	0.98 (0.82, 1.22)	0.59 (0.10, 0.79)	< 0.001
apoA1 (g/L)	1.02 (0.90, 1.09)	1.02 (0.20, 1.22)	>0.9
LP(a) (mg/L)	14 (9, 25)	7 (0, 24)	0.063
SAA (mg/L)	15 (3, 32)	1 (0, 3)	<0.001
U-occult blood (n)			0.035
no	18 (60%)	20 (77%)	
Yes	12 (40%)	4 (15%)	
U-protein (n)			0.051
no	20 (67%)	21 (81%)	
Yes	10 (33%)	3 (12%)	
J-glucose (n)			0.037
no	23 (77%)	23 (88%)	
Yes	7 (23%)	1 (3.8%)	


762

763 ¹n (%); Median (IQR)

²Fisher's exact test; Pearson's Chi-squared test; Wilcoxon rank sum test

765 eAMI, early phase of acute myocardial infarction; NSTEMI, non-ST-elevation myocardial 766 infarction; STEMI, ST-elevation myocardial infarction; BMI, body mass index; PPI, proton pump inhibitor; LM, left main; RCA, right coronary artery; LAD, left anterior descending 767 768 artery; LCX, left circumflex artery; BNP, brain natriuretic peptide; CRP, C-reactive protein; WBC, white blood cell; RDW, red cell distribution width; ALT, alanine transaminase; AST, 769 770 aspartate transaminase; GST/GLT, glutathione S-transferase; BUN, blood urea nitrogen; HbA1C, hemoglobin A1c; GSP, glycated serum protein; HDL, high-density lipoprotein 771 772 cholesterol; LDL, low-density lipoprotein cholesterol; apo, apolipoprotein; LP, lipoprotein; 773 SAA, serum amyloid A; U-, uric.





1.0


0.8


0.6


0.4


0.2


0.0














			Spearman Rho													
					-0.5			0			0.5					
					-0.0	,					0.5					
								++								Alistipes shahii:407_409
					++											Alistipes shahii:67_69 and 2 segments
						++										Alistipes shahii:2998_3000
++																Alistipes shahii:1041_1042
++																Alistipes shahii:904_908 and 5 segments
+++	++			++												Alistipes shahii:2345_2346
+++	+++		++												++	Alistipes shahii:1554_1569;1569_1597
	++														++	Alistipes shahii:1090_1091
++	++															Alistipes shahii:2710_2711
++	++		++												++	Alistipes shahii:506_508;3058_3060
	++										_					Alistipes shahii:700_702;3633_3635
+++	++														++	Alistipes shahii:3056_3059
++	++														++	Alistipes shahii:882_883;883_885
++		++													++	Alistipes shahii:3597_3600
+++	++														++	Alistipes shahii:2249_2251;2251_2252
++																Alistipes shahii:1039_1041
++																Alistipes shahii:2095_2097
++				+++					++							Alistipes shahii:2308_2314 and 14 segments
++	+++														++	Alistipes shahii:813_814 and 8 segments
++	+++														++	Alistipes shahii:575_578
++	++														++	Alistipes shahii:1450_1452;1452_1454
++	++															Alistipes shahii:373_376 and 3 segments
++	++	+++	++												+++	Alistipes shahii:57_59
		+++													+++	Alistipes shahii:3352_3355
++	++	++													+++	Alistipes shahii:3175_3178 and 4 segments
															++	
+++	++															Alistines shahii:3729 3737










f


Genes











С